OA06533A - Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique. - Google Patents

Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique.

Info

Publication number
OA06533A
OA06533A OA57113A OA57113A OA06533A OA 06533 A OA06533 A OA 06533A OA 57113 A OA57113 A OA 57113A OA 57113 A OA57113 A OA 57113A OA 06533 A OA06533 A OA 06533A
Authority
OA
OAPI
Prior art keywords
compounds
processes
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
OA57113A
Other languages
English (en)
Inventor
Dr Adrian Marxer
Dr Kurt Eichenberger
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of OA06533A publication Critical patent/OA06533A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA57113A 1979-05-18 1980-05-17 Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique. OA06533A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH466979 1979-05-18

Publications (1)

Publication Number Publication Date
OA06533A true OA06533A (fr) 1981-07-31

Family

ID=4280399

Family Applications (1)

Application Number Title Priority Date Filing Date
OA57113A OA06533A (fr) 1979-05-18 1980-05-17 Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique.

Country Status (21)

Country Link
EP (1) EP0019811A1 (fr)
JP (1) JPS55154971A (fr)
KR (1) KR830002757A (fr)
AR (1) AR228256A1 (fr)
AU (1) AU5848480A (fr)
DD (1) DD150609A5 (fr)
DK (1) DK214480A (fr)
ES (1) ES491514A0 (fr)
FI (1) FI801600A7 (fr)
GB (1) GB2052487B (fr)
GR (1) GR68453B (fr)
IE (1) IE49803B1 (fr)
IL (1) IL60086A (fr)
MA (1) MA18829A1 (fr)
NO (1) NO801469L (fr)
NZ (1) NZ193730A (fr)
OA (1) OA06533A (fr)
PL (1) PL224313A1 (fr)
PT (1) PT71251A (fr)
ZA (1) ZA802909B (fr)
ZW (1) ZW11880A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
DE3829469A1 (de) * 1988-08-31 1990-03-01 Bayer Ag Verfahren zur herstellung von substituierten n-azinyl-n'-sulfonyl-isothioharnstoffen und n-azinyl-iminodithiokohlensaeure-s,s-diester als zwischenprodukte zu ihrer herstellung
AU9302298A (en) * 1997-09-03 1999-03-22 Eli Lilly And Company Pyrimidine derivatives
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
CZ20032341A3 (cs) * 2001-01-31 2004-12-15 Synaptic Pharmaceutical Corporation Použití antagonistů GAL3 receptoru pro léčbu deprese a/nebo úzkosti
KR20040099324A (ko) 2002-03-13 2004-11-26 유로-셀티큐 에스.에이. 아릴 치환된 피리미딘 및 이것의 용도
ATE366045T1 (de) * 2002-03-15 2007-07-15 Ciba Sc Holding Ag Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
ATE468336T1 (de) 2002-03-15 2010-06-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
DE60308387T2 (de) 2002-08-02 2007-09-20 Vertex Pharmaceuticals Inc., Cambridge Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
WO2004072029A2 (fr) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de proteine kinases
AU2006279376B2 (en) 2005-08-18 2011-04-14 Vertex Pharmaceuticals Incoporated Pyrazine kinase inhibitors
TW200734327A (en) 2005-11-03 2007-09-16 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
WO2008057940A1 (fr) 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines et aminopyrimidines utiles en tant qu'inhibiteurs de protéines kinases
WO2008077086A1 (fr) 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyridines utiles comme inhibiteurs de protéine kinases
WO2008112642A1 (fr) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines utiles en tant qu'inhibiteurs des protéines kinases
EP2134709A1 (fr) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Utilisation des aminopyridines comme inhibiteurs de protéines kinases
EP2137183B1 (fr) 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines utiles en tant qu'inhibiteurs des protéines kinases
JP2010523700A (ja) 2007-04-13 2010-07-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン
CN101801959A (zh) 2007-05-02 2010-08-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
CN101679378A (zh) 2007-05-02 2010-03-24 沃泰克斯药物股份有限公司 用作激酶抑制剂的噻唑和吡唑
AR067762A1 (es) 2007-07-31 2009-10-21 Vertex Pharma Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
AU2009288200A1 (en) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
WO2010077613A1 (fr) * 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll (tlr)
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
EP4243826A1 (fr) * 2020-11-12 2023-09-20 3Z Ehf Nouveaux traitements du trouble du déficit de l'attention/hyperactivité

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (fr) * 1969-08-14 1971-02-15 Beecham Group Ltd Iminazolines

Also Published As

Publication number Publication date
PL224313A1 (fr) 1981-02-13
JPS55154971A (en) 1980-12-02
IL60086A0 (en) 1980-07-31
DD150609A5 (de) 1981-09-09
MA18829A1 (fr) 1980-12-31
DK214480A (da) 1980-11-19
ES8104279A1 (es) 1981-04-16
PT71251A (en) 1980-06-01
EP0019811A1 (fr) 1980-12-10
GB2052487A (en) 1981-01-28
AR228256A1 (es) 1983-02-15
IL60086A (en) 1984-03-30
ZA802909B (en) 1981-05-27
AU5848480A (en) 1980-11-20
FI801600A7 (fi) 1981-01-01
ES491514A0 (es) 1981-04-16
ZW11880A1 (en) 1980-12-17
NO801469L (no) 1980-11-19
KR830002757A (ko) 1983-05-30
IE801023L (en) 1980-11-18
GB2052487B (en) 1983-05-11
IE49803B1 (en) 1985-12-25
NZ193730A (en) 1982-12-21
GR68453B (fr) 1981-12-30

Similar Documents

Publication Publication Date Title
OA06533A (fr) Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique.
OA08647A (fr) Dérivés d'imidazole, procédés pour leur préparation et composition pharmaceutique les contenant.
OA06998A (fr) Composés pharmaceutiques, leurs préparation, utilisation et intermédiaires et leur préparation.
DZ473A1 (fr) Dérivés de l'acide cis-endo-2-azabicyclo/3,3,o/-octane-3-carboxylique, procédé pour leur préparation, agents contenant ces dérivés et leur utilisation.
OA07124A (fr) Dipeptides substitués, procédés pour leur préparation et compositions pharmaceutiques les contenant et leur utilisation pour l'inhibition de l'encéphalinase.
FR2708608B1 (fr) Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
SE7900685L (sv) 9-deoxi-9a-metylenisosterer av pgiŸ2 och forfarande for framstellning av dem
OA07097A (fr) Nouveaux dérivés d'arylphényléther utiles comme microbicides, procédé pour leur préparation et leur utilisation.
DZ712A1 (fr) Nouveaux dérivés de 2-2 iminobisethanol utiles comme médecaments, intermédiaires pour leur préparation et procédés pour la préparation de ces dérivés et intermédiaires.
CY2537B1 (fr) Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ418A1 (fr) Dérivés de céphalosporine, leur procédé de préparation et leur application thérapeutique.
FR2422620A1 (fr) Derives du stilbene, leur preparation et leur application en tant que medicaments
FR2708606B1 (fr) Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2445319A1 (fr) Derives de pyridine, procedes pour leur preparation et compositions pharmaceutiques les contenant
OA07699A (fr) Dérivés de la furo-(3,4-c)-pyridine leur préparation et compositions thérapeutiques contenant ces dérivés.
DZ2188A1 (fr) Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.
OA07864A (fr) Nouveaux dérivés de la vinyl-6 furo-(3,4-c) -pyridine leur préparation et compositions pharmaceutiques à base de ces composés.
OA07236A (fr) Dérivés de la triazine, procédés pour leur préparation, et compositions pharmaceutiques comportant ces dérivés.
OA06651A (fr) Nouveaux dérivés de la pipéridylbenzimidazolinone, leurs procédés de préparation, les compositions pharmaceutiques les renfermant.
BE885385A (fr) Derives de d-6-n-propylergolines, leur procede de preparation et compositions pharmaceutiques en contenant
ZA783086B (en) Benzodiazepine compounds processes for their preparation,and pharmaceutical compositions thereof
FR2422657A1 (fr) 2-(2-thenoylthio)-propionylglycine, procede pour sa preparation et compositions pharmaceutiques la contenant
OA06951A (fr) Dérivés de la thiéno-pyridinone, leur procédé de préparation et leur application thérapeutique.
OA07525A (fr) Dérivés d'acides-animés, leur préparation et utilisation ainsi que les compositions contenant ces dérivés.
OA07390A (fr) Nouveaux dérivés de carbapenem, compositions pharmaceutiques les contenant, composés intermédiaires pour leur préparation, et leurs procédés de production.